Administration of Tat-CHIP dose-dependently ameliorated ischemia-induced hyperlocomotion 1 day after ischemia induction and improved neuronal survival in the CA1 region 4 days after ischemia induction based on immunohistochemical staining for NeuN. The gene discussed is TAT; the disease is ischemia.